Monday, October 5, 2026

DRAM Prices Forecast to Double in 2026 as AI Memory Demand Outpaces Supply

DRAM prices are forecast to surge 125% for full-year 2026, with a 58-63% jump expected in Q2 alone. Micron shares are already up 162% year-to-date, signaling market conviction that memory constraints will define AI infrastructure costs through H2 2026. Cloud AI providers and compute-heavy startups face direct margin pressure.

LM Salvado

May 12, 2026

DRAM Prices Forecast to Double in 2026 as AI Memory Demand Outpaces Supply
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...
1

The driver is structural. AI model training and inference are hitting memory capacity limits. As model sizes grow and inference deployments scale across millions of requests, memory — not compute — is becoming the binding constraint on infrastructure expansion.

Cloud AI providers and AI startups face a direct cost problem. Memory hardware represents a large share of GPU server bills. A full-year price increase of this scale translates to materially higher infrastructure capex in H2 2026.1 Startups burning capital on inference workloads face compressed runways. AI SaaS companies with heavy compute costs may miss earnings estimates as hardware expenses accelerate faster than revenue growth.1

The supply side tells a different story. Memory semiconductor suppliers are positioned to benefit directly. Micron and SK Hynix are expected to outperform as prices climb.1 Both supply the high-bandwidth and standard DRAM configurations used in AI server deployments.

This creates a divergence in AI economics. Companies that lock in supply contracts or vertically integrate memory procurement gain a durable cost advantage. Those buying at spot prices through H2 2026 absorb the full impact of the surge.

The broader AI infrastructure buildout — data centers, networking, power capacity — has dominated capital allocation discussions. Memory pricing signals that the next hardware constraint is more specific: DRAM and high-bandwidth memory availability at scale.

For AI companies planning capacity through the rest of 2026, memory procurement is no longer a procurement line item. It is a strategic variable that will determine which providers can scale inference profitably and which cannot.

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com